ResearchSafe

Sermorelin (Sermorelin Acetate (GHRH 1-29))

Category: Growth Hormone. Status: Previously FDA-approved (discontinued 2008).

The biologically active fragment of GHRH (first 29 amino acids). Previously FDA-approved for GH deficiency in children. Stimulates natural pulsatile GH release. Now available through compounding pharmacies.

How it works

Binds GHRH receptors on anterior pituitary via cAMP-PKA pathway. Preserves natural feedback regulation and pulsatility unlike exogenous HGH.

Key facts

  • Molecular weight: 3,358 Da
  • Half-life: 10-20 minutes
  • Bioavailability: Moderate (SubQ)
  • Storage: Lyophilized: 2-8°C. Reconstituted: 2-8°C for 14 days.

Dosing overview

  • Typical dose: 200-300 mcg
  • Frequency: Once daily before bed
  • Duration: 3-6 months
  • Route: Subcutaneous injection

Protocol notes

  • Single nightly dose of 200-300 mcg, injected fasted before sleep.
  • Run for 3-6 months since it works by gently restoring natural GH rhythm rather than spiking it.

Reported benefits

  • Natural GH pulsatility preserved
  • Improved sleep quality
  • Body composition improvement
  • Skin elasticity
  • Long safety record

Possible side effects

  • Injection site reaction
  • Flushing
  • Headache
  • Dizziness

Research

  • Long-term sermorelin therapy for adult GH deficiency (2018): Six months increased IGF-1 by 30%, improved body composition and sleep quality without suppressing endogenous GH axis.
  • Sermorelin vs somatotropin for GH replacement (2020): Achieved 70% of HGH effects on IGF-1 with superior safety profile and preserved pituitary function.

Compare Sermorelin

Community discussions about Sermorelin

Research and educational reference only. Not medical advice.